Year: 2026

SANTA FE, N.M. and TORONTO, April 01, 2026 (GLOBE NEWSWIRE) — The Clean Energy Association of New Mexico (“CLEAN”) and Premier American Uranium (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF) are pleased to announce that PUR will serve as a Silver Sponsor of the inaugural Nuclear in New Mexico: Fueling the U.S. Nuclear Renaissance conference. The conference is taking place April 20th to 22nd, 2026, at the Hyatt Regency Tamaya Resort & Spa, located on the Santa Ana Pueblo just north of Albuquerque, New Mexico. Colin Healey, CEO of Premier American Uranium Inc., commented, “We are proud to support the inaugural Nuclear in New Mexico Conference, particularly as we continue to advance our Cebolleta Project. Following the completion of our robust PEA last year, our 2026 programs are focused on further...

CHICAGO and VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced amendments to its brand licensing agreements with wholly-owned subsidiaries of RYTHM, Inc. (“RYTHM” or “RYM”) (Nasdaq: RYM). Effective April 1, 2026, GTI Core, LLC (“GTI Core”), an indirect wholly-owned subsidiary of the Company, has amended its existing Trademark and Recipe License Agreements with VCP IP Holdings, LLC and MC Brands LLC, both wholly-owned subsidiaries of RYTHM. Under the amended agreements, licensing fees transition from revenue-based fees to recurring fixed fees of $70 million cash per year collectively for the license rights to RYTHM...

ROLLING MEADOWS, Ill., April 01, 2026 (GLOBE NEWSWIRE) — RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”), America’s THC Company, today announced amendments to its existing trademark and recipe license agreements with an indirect wholly-owned subsidiary of Green Thumb Industries Inc. (“Green Thumb”). RYTHM and Green Thumb have amended their existing trademark and recipe license agreements for the use of brand intellectual property which includes RYTHM, incredibles, Beboe, Dogwalkers, Doctor Solomon’s, &Shine, and Good Green. Effective April 1, 2026, Green Thumb will pay RYTHM an aggregate fixed annual cash fee of $70 million, subject to an annual increase equal to two times a Consumer Price Index-based escalator. “These amendments create a framework that strengthens our licensing arrangement with Green Thumb over the long...

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) — NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company’s common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at an exercise price of $3.025 per share. The offering includes participation from...

Company expands on its relationship with Flow Capital. Boston, MA, April 01, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX)(“MiniLuxe” or the “Company”), the pioneer in clean nail care and ethical nail services, is pleased to announce that Flow Capital Corporation (TSXV:FW) (“Flow Capital”), a leading provider of flexible growth capital and alternative debt solutions, has completed a follow-on investment of up to US$1.75M pursuant to its existing term loan with the Company, bringing the total amount available to the Company under the facility to up to US$7.925 million. Under the new tranche of the loan, an initial advance of US$1.35 million was funded to the Company on closing, and the Company is also eligible to receive an additional advance of up to US$400,000, subject to the satisfaction of certain financing milestones,...

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time modifier gene therapy for all ABCA4-associated retinopathiesMALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate developed for all Stargardt disease (ABCA4-associated retinopathies). “This enrollment milestone for a pivotal trial underscores the tremendous progress our team is making toward bringing a transformative...

Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or life-threatening condition MIAMI, April 01, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. “We appreciate the FDA’s decision that PAS-004 meets the criteria for Fast Track designation for this indication,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “The ability...

Multidisciplinary architecture and engineering firm to occupy approximately 5,800 square feet at the mixed-use center HOUSTON, April 01, 2026 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR), a neighborhood-focused owner and operator of open-air shopping centers in Texas and Arizona, today announced it has signed an approximately 5,800-square-foot lease with Parkhill, a multidisciplinary architecture and engineering firm, to open a new office presence in Houston at BLVD Place located in the prestigious Uptown District. The agreement highlights the type of high-credit-quality tenants that are being drawn to the mixed-use center because of its prime location and amenities. Parkhill’s second-floor workspace at BLVD Place epitomizes the type of dynamic setting that is critical for employee retention and attracting the next generation...